21,209 Shares in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Purchased by XTX Topco Ltd

XTX Topco Ltd acquired a new stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 21,209 shares of the company’s stock, valued at approximately $45,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. PFM Health Sciences LP increased its holdings in shares of Werewolf Therapeutics by 4.9% in the 3rd quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock valued at $7,205,000 after acquiring an additional 157,673 shares during the last quarter. Millennium Management LLC increased its stake in Werewolf Therapeutics by 96.4% during the second quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock valued at $2,709,000 after purchasing an additional 544,881 shares during the last quarter. State Street Corp raised its holdings in shares of Werewolf Therapeutics by 12.4% during the third quarter. State Street Corp now owns 476,439 shares of the company’s stock worth $1,010,000 after purchasing an additional 52,528 shares during the period. Acadian Asset Management LLC lifted its position in shares of Werewolf Therapeutics by 22.8% in the 2nd quarter. Acadian Asset Management LLC now owns 212,296 shares of the company’s stock worth $516,000 after buying an additional 39,413 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Werewolf Therapeutics by 103.1% in the 2nd quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock valued at $417,000 after buying an additional 86,800 shares during the period. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Price Performance

Shares of NASDAQ HOWL opened at $1.59 on Monday. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10. The firm has a market capitalization of $70.86 million, a PE ratio of -1.04 and a beta of 0.30. Werewolf Therapeutics, Inc. has a 1-year low of $1.38 and a 1-year high of $8.19. The business’s fifty day moving average price is $2.11 and its two-hundred day moving average price is $2.28.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a research note on Tuesday, November 19th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.